Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients

Autor:	Emily C. Somers, W J McCune, D. S. McConnell, Senait Fisseha, Jeffrey J. Wing, Lu Wang, Gregory M. Christman, Wendy Marder
Rok vydání:	2012
Předmět:	Adult Anti-Mullerian Hormone endocrine system medicine.medical_specialty Cyclophosphamide Endocrinology Diabetes and Metabolism Ovary Gonadotropin-releasing hormone Protective Agents Gastroenterology Article Cohort Studies Gonadotropin-Releasing Hormone Endocrinology Internal medicine medicine Humans Lupus Erythematosus Systemic Ovarian reserve Retrospective Studies Systemic lupus erythematosus Lupus erythematosus biology Fertility Preservation Obstetrics and Gynecology Anti-Müllerian hormone Fertility Agents Female medicine.disease medicine.anatomical_structure Premenopause Delayed-Action Preparations biology.protein Female Leuprolide Infertility Female Biomarkers Immunosuppressive Agents hormones hormone substitutes and hormone antagonists Follow-Up Studies Hormone medicine.drug
Zdroj:	Gynecological Endocrinology. 28:624-627
ISSN:	1473-0766 0951-3590
Popis:	We measured antimullerian hormone (AMH), a marker of ovarian reserve, in women with lupus treated with cyclophosphamide (CYC) (group I), CYC plus gonadotropin-releasing hormone agonist (GnRH-a) (group II) or neither (group III). We hypothesized that AMH would be diminished in women exposed to CYC versus women receiving adjunctive GnRH-a treatment or no CYC exposure.Forty-eight premenopausal lupus patients were retrospectively divided into three treatment groups: CYC alone (group I, n = 11), CYC + GnRH-a (group II, n = 10) and neither (group III, n = 27). Serum AMH levels between groups were compared using a nonparametric test (Wilcoxon rank-sum). Multiple linear regression adjusting for age was performed.AMH (ng/mL) levels at the last collection were significantly lower in group I versus group III (mean ± SD: 0.18 ± 0.20 group I vs 1.33 ± 1.59 group III; p = 0.015), and versus group II (mean ± SD: 0.86 ± 1.06; p = 0.018). When centered on age 30 years, average AMH levels for group I, group II and group III were 0.20, 0.44 and 1.00, respectively. When adjusted for age, AMH between all groups was significantly different (p0.0001).Posttreatment AMH levels were significantly higher among patients receiving CYC + GnRH-a compared to CYC alone, suggesting that GnRH-a coadministration mitigates CYC-induced ovarian injury.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a80d5f2a1a4cf97d4d24fdad9ddcfc4 https://doi.org/10.3109/09513590.2011.650752 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.